Adam Davidson, CEO of Trident Royalties, discusses offtake milestones and catalysts to boost FY24. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Hi RMM,
Many thanks for the post with more clarification.
I suppose we should maybe be grateful that we're with not involved with JPM instead of PH?!
https://www.standard.co.uk/business/deliveroo-ipo-float-adviser-jpmorgan-helped-short-sellers-b935097.html
Hi DP - For me SAR have always played the long game. Tim and John are not the scientists to knee jerk onto a particular bandwagon (please excuse the mixed metaphors!) just because its in the headlines. Covid was an opportunity for the pharma sector to accelerate a range potential drugs but the politicians put all their faith in the vaccine. Now we have them telling us we've got to live with it (could have told them that 2 years ago) except they haven't facilitated the therapeutics we need to achieve that. From my perspective the medical world is now in a complete mess. People aren't dying from Covid to the same degree but the waiting lists are longer and full of people who will die not from Covid but other treatable conditions. In 1801, 1802, 737 and even the SKIL platform we have something very special (I'll keep clear of the anti-ageing angle just for now!) which in my opinion means that we quite rightly skip missing the ferry boat that was Covid and wait for the Super Tanker that is Cancers, Immune and URI's.
missed the covid boat?
for me they're on track. pharma is slow. like years slow. tests and trials take ages.
bigger pharma seems to go a bit faster. but even then...it takes yonks...look at how long its taking gilead to drag out its nebulised remesdevir. sar doing very well for a small comp. check the RNS's....SAR is making moves with its Covid play.
yeah a lot of investors think covid is over...some 'covid' stocks are down...you either get out or see it as an opportunity. I read a lot of science on twitter, i like to check (on twitter) people like eric topol , bloom labs and francois balloux, that will link to upfront, often not yet peer reviewed science papers and then you can access very raw data about covid, its mutations etc and then you can make your own mind up about covid and companies like sar.
good luck with whatever decision you make.
Hi RMM,
Thanks for the very informative post. Any thought why SAR missed the COVID boat? Does it mean that it is not as good as TM thought and does not want to pursue further? It is beyond believe that not a single from them since August regarding COVID. There must be something bad and they want to delay as long as they can.
Lets get a s.p. at nearly 10p then watch it sliced to pieces right down to 4.2p and not expect some critical investors, plus the time frame of the drop is of course cause for concern. Needs some supportive RNS statement soon, if its end of Q1 then where willl the s.p. be then... frightening perspective
LTH of course
Brick
RMM - how dare you bring a calm rationale to an internet forum!!
;-)
Over the last few weeks there’s been a lot of comment on Peel, consolidation and SP manipulation. I feel its time to put a few things out there in terms of my perspective. First of all Peel. Within PH (and any other similar organisation) there are market makers, corporate brokers, researchers and analysts. The market makers are separate from the corporate brokers as are the researchers and analysts. Glass ceilings, Chinese walls or whatever you want to call them but separation is required by the compliance auditors and regulators. If you speak to the corporate broker they will tell you what they can within the rules of insider trading. The Corporate Broker does not tell the researchers and analysts how and when to do their job. Neither can he/she liaise with the market makers to force a price up or down. That would be very easy to identify and the compliance people and regulators would have shut PH down a long time ago if they did that. It may not be watertight but it certainly isn’t the sieve that some people think it is. Having worked in two industries that were both the subject of price fixing investigations (both of which were unfounded) I’m confident that PH are not rocking the boat. Having appointed them as Corporate Brokers to specifically bring on board institutions they are not required to publish the information they send out to prospective institutions nor how they are marketing to them. We simply have to wait. And I think there’s a reason why they are waiting.
SP manipulation: My personal view is that we’re watching the wrong SP. In the short term we should be watching Sierra. This week their SP has taken a bit of a bashing and bear in mind they are heavily institutionally backed. The SP bashing has come in the week when they announced they are accelerating Momo’s data. Either the data is bad and they want to get it out of the way or its good and its going to trigger a cascade of activity. I’m in the latter camp. If it was bad they’d be a lot further down because at the moment it’s the only focus of their pipeline. We also know from past experience that Sierra is a bit leaky. Meanwhile we (SAR) have in my opinion been marked down for not getting on with the Covid play, a play that I’ve always thought was a sideshow. One bit of good news, such as movement on 737 and we’ll recover the territory. So on that basis I’m watching Sierra like a hawk because if the news on Momo is good then they can turn to their investors and quite reasonably say ‘time to expand the pipeline.’ Which means that if I was PH, I’d be waiting on the news from Sierra before taking a compelling investment opportunity to potential institutions.
In conclusion I’m prepared to wait on PH because the exciting stuff in the short term is over the pond. And just to reiterate, nothing has changed in the last few months that gives me cause to review my valuations. GLA and all the above is IMHO.